Novo Nordisk AS (NVO)
105.06
+2.43
(+2.37%)
USD |
NYSE |
Nov 22, 16:00
105.08
+0.02
(+0.02%)
Pre-Market: 20:00
Novo Nordisk Revenue (TTM): 39.36B for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 39.36B |
| June 30, 2024 | 37.42B |
| March 31, 2024 | 35.54B |
| December 31, 2023 | 33.71B |
| September 30, 2023 | 30.82B |
| June 30, 2023 | 28.41B |
| March 31, 2023 | 26.38B |
| December 31, 2022 | 25.03B |
| September 30, 2022 | 24.31B |
| June 30, 2022 | 23.79B |
| March 31, 2022 | 23.24B |
| December 31, 2021 | 22.38B |
| September 30, 2021 | 21.63B |
| June 30, 2021 | 20.84B |
| March 31, 2021 | 19.92B |
| December 31, 2020 | 19.44B |
| September 30, 2020 | 19.10B |
| June 30, 2020 | 18.75B |
| March 31, 2020 | 18.84B |
| December 31, 2019 | 18.29B |
| September 30, 2019 | 18.03B |
| June 30, 2019 | 17.85B |
| March 31, 2019 | 17.72B |
| December 31, 2018 | 17.71B |
| September 30, 2018 | 17.59B |
| Date | Value |
|---|---|
| June 30, 2018 | 17.47B |
| March 31, 2018 | 17.31B |
| December 31, 2017 | 16.95B |
| September 30, 2017 | 16.80B |
| June 30, 2017 | 16.73B |
| March 31, 2017 | 16.66B |
| December 31, 2016 | 16.61B |
| September 30, 2016 | 16.56B |
| June 30, 2016 | 16.42B |
| March 31, 2016 | 16.25B |
| December 31, 2015 | 16.05B |
| September 30, 2015 | 15.94B |
| June 30, 2015 | 15.91B |
| March 31, 2015 | 15.87B |
| December 31, 2014 | 15.79B |
| September 30, 2014 | 15.62B |
| June 30, 2014 | 15.31B |
| March 31, 2014 | 15.08B |
| December 31, 2013 | 14.89B |
| September 30, 2013 | 14.57B |
| June 30, 2013 | 14.26B |
| March 31, 2013 | 13.87B |
| December 31, 2012 | 13.47B |
| September 30, 2012 | 13.10B |
| June 30, 2012 | 12.91B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
18.29B
Minimum
Dec 2019
39.36B
Maximum
Sep 2024
25.36B
Average
23.52B
Median
Revenue (TTM) Benchmarks
| Ascendis Pharma AS | 354.82M |
| Amgen Inc | 32.53B |
| AstraZeneca PLC | 51.21B |
| Viking Therapeutics Inc | -- |
| Evaxion Biotech AS | 3.295M |